Trial Profile
A phase I trial to investigate the efficacy of adoptive T cell therapy (TT 12) in oropharyngeal cancer (OPC) and cervical cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2016
Price :
$35
*
At a glance
- Drugs TT 12 (Primary)
- Indications Cervical cancer; Oropharyngeal cancer
- Focus Adverse reactions
- Sponsors Tessa Therapeutics
- 13 Jan 2016 New trial record